RBC Capital Initiates Coverage on OncoGenex Pharmaceuticals (OGXI) with an Outperform
OGXI Hot Sheet
Rating Summary:2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
RBC Capital initiates coverage on OncoGenex Pharmaceuticals (Nasdaq: OGXI) with an Outperform rating. Price target $65.
To see more analyst ratings on OGXI Click Here.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer.
To see more analyst ratings on OGXI Click Here.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Oppenheimer Starts LivePerson (LPSN) at Outperform
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
